COMPARISON BETWEEN ORAL AND INTRAVENOUS FAT TOLERANCE-TESTS IN NORMOLIPIDAEMIC SUBJECTS

被引：5

作者：

FEHER, MD

TORRENS, D

RICHMOND, W

SEVER, PS

ELKELES, RS

机构：

[1] ST MARYS HOSP,SCH MED,DEPT MED,LONDON W2 1PG,ENGLAND

[2] ST MARYS HOSP,SCH MED,DEPT CHEM PATHOL,LONDON W2 1PG,ENGLAND

来源：

HORMONE AND METABOLIC RESEARCH | 1988年 / 20卷 / 03期

关键词：

D O I：

10.1055/s-2007-1010787

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：182 / 183

页数：2

共 11 条

[1]

EISENBERG S, 1984, J LIPID RES, V25, P1012

[2] EFFECTS OF ORAL AND INTRAVENOUS FAT ADMINISTRATION ON THE LEVELS OF APOPROTEINS A-I, A-II AND C-III IN HUMAN-SUBJECTS [J].

KOGA, S ;

YAMANAGA, Y ;

FUJII, S ;

YAMAMOTO, K ;

IBAYASHI, H .

ATHEROSCLEROSIS, 1982, 41 (01) :115-124

[3] DETERMINATION OF INTRAVENOUS FAT TOLERANCE-TEST WITH INTRALIPID BY NEPHELOMETRY [J].

LEWIS, B ;

MANCINI, M ;

BOBERG, J ;

CARLSON, LA .

ATHEROSCLEROSIS, 1972, 15 (01) :83-&

[4] INTRAVENOUS FAT-TOLERANCE TEST IN ISCHEMIC HEART-DISEASE AND PERIPHERAL VASCULAR-DISEASE [J].

LEWIS, B ;

ONITIRI, AC ;

WOOTTON, IDP ;

CHAIT, A ;

SIGURDSSON, G ;

OAKLEY, CM .

CLINICAL SCIENCE AND MOLECULAR MEDICINE, 1976, 51 (04) :415-420

[5] RELATION OF ANGIOGRAPHICALLY DEFINED CORONARY-ARTERY DISEASE TO PLASMA-LIPOPROTEIN SUBFRACTIONS AND APOLIPOPROTEINS [J].

MILLER, NE ;

HAMMETT, F ;

SALTISSI, S ;

RAO, S ;

VANZELLER, H ;

COLTART, J ;

LEWIS, B .

BRITISH MEDICAL JOURNAL, 1981, 282 (6278) :1741-1744

[6] INTRAVENOUS FAT TOLERANCE - CORRELATION WITH VERY LOW-DENSITY LIPOPROTEIN APOPROTEIN B KINETICS IN MAN [J].

NICOLL, A ;

SIGURDSSON, G ;

MARSH, A ;

LEWIS, B .

ATHEROSCLEROSIS, 1977, 26 (01) :17-22

[7] POSTPRANDIAL LIPEMIA - A KEY FOR THE CONVERSION OF HIGH-DENSITY LIPOPROTEIN2 INTO HIGH-DENSITY LIPOPROTEIN3 BY HEPATIC LIPASE [J].

PATSCH, JR ;

PRASAD, S ;

GOTTO, AM ;

BENGTSSONOLIVECRONA, G .

JOURNAL OF CLINICAL INVESTIGATION, 1984, 74 (06) :2017-2023

[8]

ROSSNER S, 1974, EUR J CLIN INVEST, V4, P109

[9]

ROSSNER S, 1974, ACTA MED SCAND, V564, P7

[10]

SEVIOUR PW, 1985, DIABETES OBESITY HYP, V2, P239

← 1 2 →